Ensign Peak Advisors Inc Has $3.70 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Ensign Peak Advisors Inc boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,395 shares of the medical equipment provider's stock after purchasing an additional 7,248 shares during the quarter. Ensign Peak Advisors Inc owned about 0.06% of Lantheus worth $3,703,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. boosted its position in shares of Lantheus by 52.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 25,936 shares of the medical equipment provider's stock valued at $2,320,000 after acquiring an additional 8,959 shares during the period. Park Avenue Securities LLC boosted its holdings in Lantheus by 26.4% in the 4th quarter. Park Avenue Securities LLC now owns 2,458 shares of the medical equipment provider's stock valued at $220,000 after purchasing an additional 513 shares during the period. Empirical Asset Management LLC bought a new stake in Lantheus in the 4th quarter valued at $323,000. Procyon Advisors LLC grew its position in Lantheus by 11.1% in the 4th quarter. Procyon Advisors LLC now owns 3,613 shares of the medical equipment provider's stock worth $323,000 after purchasing an additional 361 shares during the last quarter. Finally, Shelton Wealth Management LLC increased its holdings in shares of Lantheus by 77.8% during the 4th quarter. Shelton Wealth Management LLC now owns 11,969 shares of the medical equipment provider's stock worth $1,071,000 after purchasing an additional 5,237 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Trading Down 1.4%

NASDAQ:LNTH traded down $1.11 during mid-day trading on Tuesday, hitting $77.14. The company's stock had a trading volume of 239,262 shares, compared to its average volume of 979,579. The company has a market capitalization of $5.34 billion, a price-to-earnings ratio of 12.83 and a beta of 0.23. Lantheus Holdings, Inc. has a fifty-two week low of $75.00 and a fifty-two week high of $126.89. The stock has a fifty day moving average of $96.65 and a 200-day moving average of $92.87.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company's quarterly revenue was up .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.69 earnings per share. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. StockNews.com upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Truist Financial lowered their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, B. Riley cut their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $132.67.

Insiders Place Their Bets

In other news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock worth $6,016,046 over the last three months. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.